Highlights

Roth Capital Starts Coverage on AEterna Zentaris (AEZS)

 Source: ABMN Staff   |   Publish date: Thu, 20 Sep 2012, 08:04 AM   |    >> Read article in News website

Research analysts at Roth Capital began coverage on shares of AEterna Zentaris (NASDAQ: AEZS) in a report released on Thursday. The firm set a “buy” rating on the stock.

AEterna Zentaris opened at 0.6801 on Thursday. AEterna Zentaris has a 1-year low of $0.38 and a 1-year high of $2.17. The company’s market cap is $76.4 million.

A number of other firms have also recently commented on AEZS. Analysts at Oppenheimer reiterated a “perform” rating on shares of AEterna Zentaris in a research note to investors on Thursday, August 16th. Analysts at RBC Capital cut their price target on shares of AEterna Zentaris from $0.70 to $0.55 in a research note to investors on Thursday, August 16th. They now have a “sector perform” rating on the stock.

Aeterna Zentaris Inc. (Aeterna Zentaris) is a drug development company specialized in oncology and endocrine therapy.

Share this

  Be the first to like this.
 


 

2936  2874  1048  1501 

ActiveGainersLosers
Top 10 Active Counters
 NameLastChange 
 CLF 4.168+1.098 
 CPXX 29.985+12.455 
 BAC 14.975+0.095 
 EEM 33.23+0.15 
 MU 12.335+0.025 
 GDX 22.545+0.265 
 AAPL 100.16-0.19 
 AMD 4.635+0.035 
 TVIX 2.40-0.04 
 SPY 210.45+0.21 
Partners & Brokers